• Link to AUCVM Facebook page
  • Link to AUCVM Twitter page
  • Link to AUCVM Google Plus page
  • Link to AUCVM Instagram page
  • Link to AUCVM YouTube page
 
menu button
2020 Annual Conference and the J.T. Vaughn Equine Conference

Boehringer Ingelheim

Boehringer Ingelheim is the second largest animal health business in the world, with net sales of $4.5 billion (4 billion euros) in 2019 and presence in more than 150 markets. As the lives of animals and humans are intertwined, our 10,000 global employees are dedicated to enhancing the well-being of both – through science and innovation, as well as through their commitment and passion.

Respect for animals, people and the environment is at the heart of what we do. We develop medicines, services and innovative digital technologies to protect animals from disease and pain. We support our customers in taking care of the health of their animals and protect our communities against life- and society- threatening diseases. Boehringer Ingelheim Animal Health has a significant presence in the United States, with more than 3,100 employees in places that include Georgia, Missouri, Iowa, Minnesota, New Jersey and Puerto Rico. To learn more, visit www.boehringer-ingelheim.us, www.facebook.com/BoehringerAHUS or www.twitter.com/Boehringer_AH.

 

Boehringer Ingelheim

Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim has been independent and family-owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.

As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. In 2019, Boehringer Ingelheim achieved net sales of $21.3 billion (19 billion euros). Our significant investment of over $3.9 billion (3.5 billion euros) in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.

We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.

Nexgard Powerful Flea and Tick Protection
Heartgard: The Real-Beef Chew
Recombitek / Purevax / Imrab vaccines
PetPro Connect Free Mobile Based Telemedicine Platform

Visit our website